Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.
复制标题
DOI：
10.5858/arpa.2021-0295-cp
复制
发表时间：
2022-05-01
影响因子：
4.6
通讯作者：
Perry, Arie
中科院分区：
文献类型：
--
作者：
Brat, Daniel J.;Aldape, Kenneth;Bridge, Julia A.;Canoll, Peter;Colman, Howard;Hameed, Meera R.;Harris, Brent T.;Hattab, Eyas M.;Huse, Jason T.;Jenkins, Robert B.;Lopez-Terrada, Dolores H.;McDonald, William C.;Rodriguez, Fausto J.;Souter, Lesley H.;Colasacco, Carol;Thomas, Nicole E.;Yount, Michelle Hawks;van den Bent, Martin J.;Perry, Arie
在过去的十年中，随着分子生物标志物的出现，弥漫性胶质瘤患者的诊断和临床管理迅速发展，这些标志物被用于对风险进行分类、分层和预测治疗反应，以获得最佳的临床护理。为儿童和成人弥漫性胶质瘤患者的分子生物标志物检测提供循证建议，并为最佳诊断、风险分层和预测提供适当的实验室检测和生物标志物选择指导。美国病理学家学会召集了一个专家小组，对文献进行了系统的回顾，并提出了建议。对文献进行了系统的回顾，以解决首要问题，“需要哪些辅助测试来对弥漫性胶质瘤进行分类并充分告知患者的临床管理？”建议来源于高质量的证据、公开的意见反馈和专家小组的共识。建立了13项建议和3项良好实践声明，以指导病理学家和治疗医生采用最合适的方法和分子生物标志物，包括在实验室测试中，为弥漫性胶质瘤患者的临床管理提供信息。基于证据的分子生物标志物检测的实验室结果纳入弥漫性胶质瘤的综合诊断，为患者管理提供了可重复和临床有意义的信息。
The diagnosis and clinical management of patients with diffuse gliomas have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk and predict treatment response for optimal clinical care. To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with diffuse gliomas and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification and prediction. The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching question, “What ancillary tests are needed to classify diffuse gliomas and sufficiently inform the clinical management of patients?” Recommendations were derived from quality of evidence, open comment feedback, and expert panel consensus. Thirteen recommendations and 3 good practice statements were established to guide pathologists and treating physicians on the most appropriate methods and molecular biomarkers to include in laboratory testing to inform clinical management of patients with diffuse gliomas. Evidence-based incorporation of laboratory results from molecular biomarker testing into integrated diagnoses of diffuse gliomas provides reproducible and clinically meaningful information for patient management.
DOI：
10.1111/bpa.12826
发表时间：
2020-05
期刊：
Brain pathology (Zurich, Switzerland)
影响因子：
--
作者：
Lin AL;Rosenblum M;Mellinghoff IK;Tabar VS;Ogilvie S;Schaff L;Yang TJ;Young RJ;Taylor BS;Jonsson P;Bale TA
通讯作者：
Bale TA
异氯酸盐脱氢酶1基因突变与临床低级神经胶质瘤的预后有关。
影响因子：
3.7
作者：
Li MY;Wang YY;Cai JQ;Zhang CB;Wang KY;Cheng W;Liu YW;Zhang W;Jiang T
通讯作者：
Jiang T
影响因子：
--
作者：
Wang PF;Liu N;Song HW;Yao K;Jiang T;Li SW;Yan CX
通讯作者：
Yan CX